Efalizumab (trade name Raptiva Genentech Merck Serono) is a formerly available medication designed to treat autoimmune diseases originally marketed to treat psoriasis. As implied by the suffix -zumab it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection.
This page contains content from the copyrighted Wikipedia article "Efalizumab"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.